Novartis says Phase II study of cancer drug Tasigna shows impressive response


novartis ZURICH (AFX) - Novartis AG said new data from a Phase II study with cancer drug Tasigna shows impressive response rates in leukaemia patients with resistance or intolerance to treatment with Glivec.

According to the data, which forms the basis for US and EU regulatory approvals, Tasigna eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of the adult patients.

The reductions may be the highest ever reported with a targeted therapy at a minimum of six months follow-up, the Basel-based drugs maker said.

source - AFX 


Previous entry: Hope for vitamin D research to cut skin cancer rate

Next entry: New cancer Web portal for young adults

Find recent content on the main index or look in the archives to find all content.